EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Development and validation of an analytical method for trace‐level quantification of genotoxic nitrosamine impurities in losartan and hydrochlorothiazide fixed‐dose combination tablets using ultra performance liquid chromatography triple quadrupole mass spectrometry

Ravi Patel iD, Sanjay Purohit, Ravisinh Solanki iD, Dignesh Khunt iD, Chhaganbhai Patel, Rucha Patel iD, Shalin Parikh iD

Rapid Communications in Mass Spectrometry · 2023

DOI: 10.1002/rcm.9488 ↗

At a glance

Übersichtsarbeit in Rapid Communications in Mass Spectrometry, 2023. Written by Ravi Patel and 6 co-authors. Institution: Department of Quality Assurance, Graduate School of Pharmacy, Gujarat Technological University, Gandhinagar, India. Major MEDLINE topics: Losartan, Nitrosamines. Cited 17 times so far (Crossref); 29 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Rationale

Since June 2018, globally large numbers of pharmaceuticals have been recalled due to the unexpected presence of nitrosamines. Beginning with the class of pharmaceuticals known as sartans, subsequent lines of inquiry included antidiabetic medicines, antihistamines, and antibiotics. A critical review of the U.S. Food and Drug Administration database reveals that the highest number of products recall due to the presence of unacceptable levels of nitrosamines were losartan potassium drug products and their coformulations with other drug substances. The problem can be mainly attributed to naively adopted approval revisions and the lack of sufficient current analytical technologies to detect those contaminants in time. In this work, we developed a specific, selective, accurate, precise, and robust ultra‐performance liquid chromatography‐triple quadrupole‐mass spectrometry (UPLC‐TQ‐MS/MS) method for the estimation of eight genotoxic nitrosamine impurities in losartan and hydrochlorothiazide (HCTZ) tablets, which is the only fixed‐dosage combination approved by the USFDA to treat hypertension.

Methods

All the nitrosamine impurities along with the drug substances were separated using an Agilent Pursuit XRs Ultra diphenyl column (150 × 2.0 mm, 2.8 μm) with mobile phase A (0.1% formic acid in water) and mobile phase B (0.1% formic acid in methanol) at a flow rate of 0.4 ml/min using the gradient elution program. The proposed method was validated per ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) Q2 (R1) guidelines to ensure the method is suitable for its intended purpose.

Results

Limit of detection and limit of quantification were obtained in the range of 0.25–0.5 ng/mL, which was very low compared to levels specified by the USFDA, European Medicines Agency (EMA), and other regulatory authorities that ensure the sensitivity of the method in its entire life cycle.

Conclusions

The developed method can be incorporated into an official monograph and applied for routine quality control analysis of losartan and HCTZ fixed‐dose combination tablets.

Subjects

MeSH terms (MEDLINE)

LosartanNitrosaminesHumansHydrochlorothiazideChromatography, High Pressure LiquidTandem Mass SpectrometryChromatography, LiquidTabletsFormates

Substances

LosartanNitrosaminesHydrochlorothiazideTabletsformic acidFormates

Authors and institutions

  • Department of Quality Assurance, Graduate School of Pharmacy, Gujarat Technological University, Gandhinagar, India.
  • Department of Pharmaceutics, Graduate School of Pharmacy, Gujarat Technological University, Gandhinagar, India.
  • Department of Medicinal Chemistry, Shri Sarvajanik Pharmacy College, Mehsana, India.
  • Regulatory Affairs Division, JAMP INDIA Pharmaceutical Pvt. Ltd., Ahmedabad, India.
  • Analytical Development Division, Senores Pharmaceuticals, Ahmedabad, India.

ORCID profiles: Ravi Patel, Ravisinh Solanki, Dignesh Khunt, Rucha Patel, Shalin Parikh

Cite

APA

Patel, R., Purohit, S., Solanki, R., Khunt, D., Patel, C., Patel, R., & Parikh, S. (2023). Development and validation of an analytical method for trace‐level quantification of genotoxic nitrosamine impurities in losartan and hydrochlorothiazide fixed‐dose combination tablets using ultra performance liquid chromatography triple quadrupole mass spectrometry. Rapid Communications in Mass Spectrometry. https://doi.org/10.1002/rcm.9488

Vancouver

Patel R, Purohit S, Solanki R, Khunt D, Patel C, Patel R, et al. Development and validation of an analytical method for trace‐level quantification of genotoxic nitrosamine impurities in losartan and hydrochlorothiazide fixed‐dose combination tablets using ultra performance liquid chromatography triple quadrupole mass spectrometry. Rapid Communications in Mass Spectrometry. 2023. doi:10.1002/rcm.9488

BibTeX
@article{Patel2023,
  author = {Patel, Ravi and Purohit, Sanjay and Solanki, Ravisinh and Khunt, Dignesh and Patel, Chhaganbhai and Patel, Rucha and Parikh, Shalin},
  title = {Development and validation of an analytical method for trace‐level quantification of genotoxic nitrosamine impurities in losartan and hydrochlorothiazide fixed‐dose combination tablets using ultra performance liquid chromatography triple quadrupole mass spectrometry},
  journal = {Rapid Communications in Mass Spectrometry},
  year = {2023},
  doi = {10.1002/rcm.9488}
}
Start for free →